Compare · RXST vs STAA
RXST vs STAA
Side-by-side comparison of RxSight Inc. (RXST) and STAAR Surgical Company (STAA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RXST and STAA operate in Ophthalmic Goods (Health Care), so they compete in similar markets.
- STAA is the larger of the two at $1.38B, about 6.6x RXST ($209.5M).
- Over the past year, RXST is down 35.8% and STAA is up 55.7% - STAA leads by 91.5 points.
- STAA has been more active in the news (9 items in the past 4 weeks vs 4 for RXST).
- Both have 25 recent analyst ratings on file.
- Company
- RxSight Inc.
- STAAR Surgical Company
- Price
- $4.97-1.97%
- $26.96-2.93%
- Market cap
- $209.5M
- $1.38B
- 1M return
- +3.54%
- -6.86%
- 1Y return
- -35.79%
- +55.72%
- Industry
- Ophthalmic Goods
- Ophthalmic Goods
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 4
- 9
- Recent ratings
- 25
- 25
RxSight Inc.
RxSight, Inc., a medical technology company, develops light adjustable lens (LAL) to improve uncorrected visual acuity that can be adjusted enhance uncorrected visual acuity after cataract surgery. It also offers RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is based in Aliso Viejo, California.
STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Latest RXST
- RxSight Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- RxSight Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement
- Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs
- Director Warner Robert Keith was granted 37,037 shares, increasing direct ownership by 90% to 78,076 units (SEC Form 4)
- Director Palmisano Robert J was granted 37,037 shares, increasing direct ownership by 90% to 78,076 units (SEC Form 4)
- Director Maniar Shweta was granted 37,037 shares, increasing direct ownership by 204% to 55,172 units (SEC Form 4)
- Director Fountain Tamara was granted 37,037 shares, increasing direct ownership by 104% to 72,582 units (SEC Form 4)
- Director Link William J Phd was granted 37,037 shares, increasing direct ownership by 98% to 74,892 units (SEC Form 4)
- Director Corley Jesse Anderson was granted 37,037 shares, increasing direct ownership by 75% to 86,227 units (SEC Form 4)
Latest STAA
- SEC Form S-8 filed by STAAR Surgical Company
- SEC Form 4 filed by Director Wang Christopher Min Fang
- SEC Form 4 filed by Director Lebuhn Richard T.
- SEC Form 4 filed by Director Bradsher Neal C
- Director Butcher Arthur C converted options into 5,341 shares, increasing direct ownership by 127% to 9,549 units (SEC Form 4)
- SEC Form 4 filed by Director Zhou Lilian Yansheng
- STAAR Surgical Company filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Silverman Lou converted options into 10,683 shares, increasing direct ownership by 2,249% to 11,158 units (SEC Form 4)
- Director Jiang Wei converted options into 10,683 shares, increasing direct ownership by 16% to 77,127 units (SEC Form 4)
- Director Zhou Lilian Yansheng was granted 3,530 shares, increasing direct ownership by 77% to 8,101 units (SEC Form 4)